Summit Therapeutics Inc.

NasdaqGM:SMMT 주식 보고서

시가총액: US$14.7b

Summit Therapeutics 미래 성장

Future 기준 확인 0/6

Summit Therapeutics의 수익이 증가할 것으로 예상됨입니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장28.3%
매출 성장률85.4%
향후 자기자본 수익률-29.4%
애널리스트 커버리지

Low

마지막 업데이트18 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Nov 08
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Oct 04

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Sep 09

Summit Therapeutics May Have Further Upside From Here

Aug 03

Summit Therapeutics Stock: Plunging Despite A Win?

May 31

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

May 06

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Jan 30

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics slips on plans to terminate study for lead candidate

Oct 04

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29
Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

수익 및 매출 성장 예측

NasdaqGM:SMMT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202648N/AN/A-2864
12/31/2025N/AN/AN/A-1654
12/31/2024N/AN/AN/A-1484
9/30/2024N/A-197-128-113N/A
6/30/2024N/A-162-98-97N/A
3/31/2024N/A-116-94-94N/A
12/31/2023N/A-615-552-77N/A
9/30/2023N/A-598-527-52N/A
6/30/20230-598-521-46N/A
3/31/20230-600-511-36N/A
12/31/20221-79-42-42N/A
9/30/20221-87-57-56N/A
6/30/20222-85-72-71N/A
3/31/20222-93-72-71N/A
12/31/20212-89-73-73N/A
9/30/20212-75-72-71N/A
6/30/20211-73-65-64N/A
3/31/20211-64-64-64N/A
12/31/20201-53-49-48N/A
9/30/20201-51-49-49N/A
6/30/20201-40-38-37N/A
3/31/2020-5-31-18-18N/A
12/31/20191-32-23-23N/A
10/31/201926-28-24-23N/A
7/31/201924-27-20-19N/A
4/30/20197212-24-24N/A
1/31/20195711-35-35N/A
10/31/2018702-36-36N/A
7/31/20187211N/A-45N/A
4/30/201827-29N/A-19N/A
1/31/201820-29N/A-21N/A
10/31/201715-18N/A-20N/A
7/31/201712-23N/A31N/A
4/30/20175-27N/A14N/A
1/31/20173-27N/A15N/A
10/31/20161-29N/A15N/A
7/31/20161-33N/A-26N/A
4/30/20161-32N/A-29N/A
1/31/20162-29N/A-24N/A
10/31/20152-25N/A-23N/A
7/31/20153-20N/A-20N/A
4/30/20153-19N/A-21N/A
1/31/20153-17N/A-17N/A
10/31/20143-17N/A-16N/A
7/31/20144-17N/A-16N/A
4/30/20144-13N/A-11N/A
1/31/20143-10N/A-10N/A

애널리스트 미래 성장 예측

수입 대 저축률: SMMT 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: SMMT 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: SMMT 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: SMMT 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: SMMT 은(는) 내년에 수익이 없을 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: SMMT (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견